Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.

NCT01302600 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Spinal Muscular Atrophy Type II
Spinal Muscular Atrophy Type III Non Ambulant

Interventions

DRUG: Olesoxime
DRUG: Placebo

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]